Table 1.
Description of the cohort.
| Controls (n = 22) | Mild (n = 40) | Severe (n = 44) | p | |
|---|---|---|---|---|
| Sex | ||||
| Female | 14 (64%) | 20 (50%) | 5 (11%) | < 0.0001+ |
| Male | 8 (36%) | 20 (50%) | 39 (89%) | |
| Age (years) | ||||
| Median | 49 | 68 | 60 | < 0.0001# |
| Mean (SD) | 44.5 ± 12.9 | 69.0 ± 14.9 | 56.9 ± 10.6 | |
| Range | 22–65 | 44–99 | 29–79 | |
| BMI (kg/m2) | ||||
| Median | 22.0 | 25.6 | 29.9 | 0.0088# |
| Mean (SD) | 23.6 ± 5.4 | 28.4 ± 8.0 | 29.4 ± 5.5 | |
| Range | 18.1–38.7 | 13.3–57.7 | 16.8–39.1 | |
| Missing data | 5 (23%) | 13 (33%) | 4 (9.1%) | |
| Length of hospital stay (days) | < 0.0001* | |||
| Median | – | 12.0 | 34.5 | |
| Mean (SD) | – | 14.8 ± 11.7 | 36.6 ± 18.6 | |
| Range | – | 3–64 | 4–80 | |
| Deaths | – | 0 (0%) | 25 (57%) | < 0.0001° |
| Treatments | ||||
| Hydroxychloroquine | – | 5 (13%) | 12 (27%) | 0.1096° |
| Dexamethasone | – | 11 (28%) | 34 (77%) | < 0.0001° |
| Lopinavir/Ritonavir | – | 7 (18%) | 27 (61%) | < 0.0001° |
| Tocilizumab | – | 0 (0%) | 7 (16%) | 0.0126° |
| Anakinra | – | 5 (13%) | 13 (30%) | 0.0674° |
| Remdesivir | – | 0 (0%) | 4 (9.1%) | 0.1177° |
| Pulmonary lesions | ||||
| Mild (< 10%) | – | 13 (33%) | 2 (4.5%) | 0.0001+ |
| Moderate (10–25%) | – | 17 (42%) | 9 (19%) | |
| Extensive (25–50%) | – | 8 (20%) | 12 (27.5%) | |
| Severe (50–75%) | – | 2 (5.0%) | 17 (39%) | |
| Critical (> 75%) | – | 0 (0%) | 4 (9%) | |
| PaO2/FiO2 | ||||
| Median | – | – | 166.0 | – |
| Mean (SD) | – | – | 210 ± 109 | – |
| Range | – | – | 57–466 | – |
| SAPS II score | ||||
| Median | – | – | 60.0 | – |
| Mean (SD) | – | – | 38.82 ± 15.1 | |
| Range | – | – | 16–81 | |
| Hospital acquired pneumonia | – | 3 (7.5%) | 37 (84%) | < 0.0001° |
| Time elapsed between FS1 and blood sampling (days) | ||||
| Median | – | 16.5 | 19 | 0.1357* |
| Mean (SD) | – | 18.2 ± 11.5 | 22.6 ± 14.1 | |
| Range | – | 3–57 | 4–64 | |
| Blood count (mean ± SD) | ||||
| Leucocytes (G/L) | 6.8 ± 2.2 | 7.4 ± 4.2 | 13.2 ± 5.8 | < 0.0001# |
| Neutrophils (G/L) | 4.4 ± 1.6 | 5.1 ± 3.9 | 11.0 ± 5.7 | < 0.0001# |
| Monocytes (G/L) | 0.45 ± 0.15 | 0.65 ± 0.31 | 0.74 ± 0.54 | 0.0861# |
| Lymphocytes (G/L) | 1.8 ± 0.5 | 1.4 ± 0.6 | 1.2 ± 0.8 | 0.0477# |
| Eosinophils (G/L) | 0.13 ± 0.14 | 0.099 ± 0.086 | 0.17 ± 0.26 | 0.2190# |
| Basophils (G/L) | 0.04 ± 0.02 | 0.023 ± 0.017 | 0.030 ± 0.043 | 0.2151# |
*Student t-test ; +Chi-square test; °Fisher’s exact test; #ANOVA. FS1 : first day of functional signs.